Delivery Order SPE2DB25D9363-SPE2DB25FUFSN

Award Date 4/29/25
Potential Completion Date 4/30/25
Potential Value $3.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $11,500.30, is for the delivery of MENQUADFI VIAL 0.5ML medical supplies. DMS Pharmaceutical Group holds a larger single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $3,897.65, is for the delivery of MENQUADFI VIAL 0.5ML medical supplies. The award has an ultimate completion date of May 1, 2025 and was made on April 30, 2025. DMS Pharmaceutical Group Inc. has a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,559.06 contract is for the delivery of 4568025978 MENQUADFI VIAL 0.5ML medical supplies. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program, which enables the agency to issue...
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $11,692.95 contract is for the delivery of 4,567,994,749 units of the MENQUADFI VIAL 0.5ML medical product. The contract has an ultimate completion date of April 17, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $7,015.77, is for the delivery of MENQUADFI VIAL 0.5ML pharmaceutical products. The contract has an ultimate completion date of April 30, 2025 and does not have a set-aside designation. DMS Pharmaceutical Group Inc. is a pharmaceutical wholesaler that specializes in providing a range of pharmaceutical products, including...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $11,692.95, is for the delivery of MENQUADFI VIAL 0.5ML pharmaceutical products. The contract is a firm fixed-price delivery order and does not have a set-aside designation. DMS Pharmaceutical Group Inc. is the prime contractor and holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $2,338.59 contract is for the delivery of MENQUADFI VIAL 0.5ML medication, with a period of performance through November 2024. DMS Pharmaceutical Group holds a large single-award Indefinite Delivery Contract (IDC) with DLA under the SPE2DB program, valued at $499,999,999 and valid...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract award, valued at $2,338.59, is for the delivery of MENQUADFI VIAL 0.5ML pharmaceutical products. This award is a delivery order under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA, valued at $499,999,999 and valid through November 2026. The IDC allows the DLA to issue firm fixed-price delivery orders for a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $3,118.12, is for the delivery of 4568025982 MENQUADFI VIAL 0.5ML, a pharmaceutical product. The contract has a firm fixed-price pricing type and an ultimate completion date of April 17, 2025. DMS Pharmaceutical Group Inc. is the prime contractor and does not have any listed subcontractors. The contract is not associated with a...
This federal contract award, valued at $1,559.06, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of "MENQUADFI VIAL 0.5ML" medical products, with an ultimate completion date of March 26, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA...
  • SPE2DB25D9363
    Indefinite Delivery Contract
  • SPE2DB25D9363-SPE2DB25FUFSN
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of MENQUADFI VIAL 0.5ML, with a ceiling value of $3,118.12 and a period of performance through April 30, 2025. The contract is not set aside and was awarded on April 29, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items supporting medical supply needs of military health facilities worldwide.

Generated 8/3/25, 1:21 AM